In the dynamic landscape of biotech, securing the right funding is the heartbeat of progress. For innovative startups in this field, the journey from breakthrough idea to market success requires strategic financial support. Here are some prime routes for biotech companies to secure the capital they need. Click here to download the document.
Biotech research and development serve as the bedrock of groundbreaking advancements, but the journey often demands substantial financial backing. CEOs spearheading these ventures find themselves seeking strategic funding avenues to nurture their companies’ growth and innovation. Licensing emerges as a powerful and versatile approach, presenting an array of opportunities to secure the capital necessary for […]
SHANGHAI AND PRINCETON, N.J. JUNE 09, 2023KYBORA Life Sciences, a global advisory firm dedicated to facilitating enduring success for life sciences companies, is pleased to announce the appointment of Wang Zhi as Executive Vice President (EVP) and Managing Director of KYBORA Life Sciences (Shanghai) Co., Ltd., effective June 21, 2023.Wang Zhi brings extensive experience and […]
In this report (download here) , Q1 2023 Global Biopharma Market Trends and News, we cover the key Biotech/Pharma trends and developments in seven regions (US, Europe, Japan, India, China, Latin America, and Africa) for the first quarter of 2023. We have also covered the major news and developments of the top ten companies in […]
KYBORA’s mission is to help life science companies achieve enduring success. Khai’s addition to our team allows us to provide additional value to our clients in China and Asia.
KYBORA is pleased to announce that its client Megalabs has acquired acquired Fr!ska.
KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.
KYBORA and its Chinese translation (pronounced KAI-BO-RUI) have both been granted official trademark status by the People’s Republic of China.
KYBORA is please to announce that its client Pint Pharma has completed an agreement to commercialize Orladeyo in Latin America
KYBORA is pleased to announce the global licensing of ACT-01 from Accure Therapeutics to Oculis. This transaction further demonstrates KYBORA’s expertise in delivering global biopharma licensing deals and in the ophtalmology space
